SCHEMBL6785296

SCHEMBL6785296

CCOC(=O)c1cn2c3c(cc(C=O)cc3c1=O)OC(c1cccc(O[Si](C)(C)C(C)(C)C)c1)C2

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.33
HSP90AA1 P07900 1/20 0.32
HSP90AB1 P08238 1/20 0.32
LMNA P02545 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
MEN1 O00255 4/20 0.31
KMT2A Q03164 4/20 0.31
SMN1; SMN2 Q16637 2/20 0.31
MAOB P27338 1/20 0.31
THRB P10828 2/20 0.31
MAPT P10636 2/20 0.31
ALDH1A1 P00352 2/20 0.30
HTT P42858 1/20 0.30
PTPN7 P35236 1/20 0.30
DUSP3 P51452 1/20 0.30
DUSP6 Q16828 1/20 0.30
KDM4E B2RXH2 2/20 0.30
HPGD P15428 2/20 0.30
RXFP1 Q9HBX9 1/20 0.30
CYP2C19 P33261 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6781699 0.89 GAA (0.33) GAALMNATDP1MEN1KMT2A
SCHEMBL6780920 0.84 RXFP1 (0.36) GAALMNAKMT2ASMN1; SMN2MAPT
SCHEMBL6777893 0.81 MAPT (0.32) GAALMNATDP1MEN1KMT2A
SCHEMBL6781745 0.70 MAPT (0.33) GAALMNATDP1MEN1KMT2A
SCHEMBL6776971 0.69 ALDH1A1 (0.45) GAALMNASMN1; SMN2MAPTALDH1A1
SCHEMBL6782434 0.67 ELANE (0.38) GAALMNATDP1MEN1KMT2A
SCHEMBL3481137 0.61 TSHR (0.42) GAASMN1; SMN2MAOBALDH1A1KDM4E
SCHEMBL1656366 0.61 CA12 (0.43) GAALMNAMEN1KMT2ASMN1; SMN2
SCHEMBL1010834 0.60 HSP90AA1 (0.50) HSP90AA1HSP90AB1TDP1MEN1KMT2A
SCHEMBL14529462 0.60 CYP1A2 (0.44) LMNATDP1MEN1KMT2AMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1299395-B1 OXAZINOQUINOLONES USEFUL FOR THE TREATMENT OF VIRAL INFECTIONS UPJOHN CO (US) 2004-09-15 EP disclosed
US-6673793-B2 N-(4-CHLOROBENZYL)-9-(MORPHOLIN-4-YLMETHYL)-7-OXO-2-(S)-PYRIDIN-2-YL-2,3-DIHYDRO-7H-(1,4) OXAZINO(2,3,4-IJ)QUINOLINE-6-CARBOXAMIDE, FOR EXAMPLE; INHIBITING A VIRAL DNA POLYMERASE; TREATING VIRUSES OF HERPES FAMILY PHARMACIA & UPJOHN CO. 2004-01-06 US disclosed
US-20020103170-A1 Oxazinoquinolones useful for the treatment of viral infections PHARMACIA & UPJOHN COMPANY 2002-08-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020103170-A1 Oxazinoquinolones useful for the treatment of viral infections ZC3HAV1, RPL5, ZC3HAV1L GAA 590/4885HSP90AA1 1652/4885HSP90AB1 1293/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.